WJPPS Citation

Login

Search

News & Updation

  • Updated Version
  • WJPPS introducing updated version of OSTS (online submission and tracking system), which have dedicated control panel for both author and reviewer. Using this control panel author can submit manuscript
  • Call for Paper
    • WJPPS  Invited to submit your valuable manuscripts for Coming Issue.
  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.
  •  
  • New Impact Factor
  • WJPPS Impact Factor has been Increased to 8.025 for Year 2024.

  • ICV
  • WJPPS Rank with Index Copernicus Value 84.65 due to high reputation at International Level

  • Scope Indexed
  • WJPPS is indexed in Scope Database based on the recommendation of the Content Selection Committee (CSC).

  • WJPPS: NOVEMBER ISSUE PUBLISHED
  • NOVEMBER 2024 Issue has been successfully launched on NOVEMBER 2024.

Abstract

CLINICAL CASE OF A CHILD WITH TYPE 1 DIABETES MELLITUS AND AUTOIMMUNE ENCEPHALOPATHY

Margarita Alexieva Archinkova*, Maia Mincheva Konstantinova, Radka Savova Hristova, Daniel Iliev Iliev, Ivan Olegovich Litvinenko

ABSTRACT

Autoimmune etiology is being increasingly discussed as a cause of encephalopathy and intractable epilepsy in children and teenagers. Suspicion for autoimmune encephalopathy arises in patients with another established autoimmune disorder. We present a girl diagnosed with type 1 diabetes at the age of 5 years. The initial immunological laboratory data showed positive autoantibodies: GAD- 65 Ab = 92.5 IU/ml (n. v.

Keywords: autoimmune encephalopathy, autoimmune epilepsy, type 1 diabetes mellitus, anti-glutamic acid decarboxylase antibodies (GAD-Ab).


[Download Article]     [Download Certifiate]

Call for Paper

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More

Online Submission

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More

Email & SMS Alert

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More